版本:
中国

Allergan, Argentum settle patent dispute over eye drug Restasis

April 18 U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis.

The agreement gives Argentum the right to sell the copycat version of Restasis before the patents covering the drug expire, Argentum said. It did not disclose when it would launch the generic product.

Restasis, which was approved by the U.S. Food and Drug Administration in 2002, is used to treat dry eye. (Reporting by Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐